Welcome to our dedicated page for Acumen Pharmaceuticals SEC filings (Ticker: ABOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Understanding how a clinical-stage biotech finances multi-year Alzheimer鈥檚 trials is tough. Acumen Pharmaceuticals鈥� 10-K details R&D burn rates, dilution risk and the science behind sabirnetug, yet the narrative spans hundreds of pages filled with immunology jargon. Quarterly 10-Q updates land while insiders file Form 4s minutes after the market closes. Investors who need those data points fast often ask, 鈥淲here can I find Acumen Pharmaceuticals鈥� quarterly earnings report 10-Q filing?鈥� or 鈥淗ow do I monitor Acumen Pharmaceuticals insider trading Form 4 transactions in real time?鈥�
Stock Titan鈥檚 AI reads every line the moment a document hits EDGAR. Our platform turns an intimidating 8-K about a Phase 2 interim readout into plain-English bullet points, flags cash-runway shifts inside the MD&A, and surfaces Acumen Pharmaceuticals executive stock transactions Form 4. Whether you want 鈥淎cumen Pharmaceuticals annual report 10-K simplified,鈥� 鈥淎cumen Pharmaceuticals proxy statement executive compensation,鈥� or 鈥淎cumen Pharmaceuticals 8-K material events explained,鈥� we鈥檝e already summarized it.
All SEC documents appear in one feed with:
- AI-powered summaries for quick context
- AG真人官方-time alerts on Acumen Pharmaceuticals Form 4 insider transactions
- Side-by-side Acumen Pharmaceuticals earnings report filing analysis for each 10-Q
That means you can:
- Track cash usage against projected trial milestones
- Compare R&D spend quarter over quarter
- Spot insider buying before material announcements
If you have ever searched for 鈥渦nderstanding Acumen Pharmaceuticals SEC documents with AI鈥� or needed 鈥淎cumen Pharmaceuticals SEC filings explained simply鈥� before a decision, this page answers it. Complex biotech disclosures are distilled into what matters: the progress of sabirnetug, funding runway, and the timing of clinical catalysts. No scrolling, no medical dictionaries鈥攋ust the essentials, updated the second Acumen hits 鈥渟ubmit.鈥�
Acumen Pharmaceuticals (ABOS) is reported to have a combined 3,417,075 shares beneficially owned by Sands-linked reporting persons, representing 5.6% of the outstanding common stock based on 60,573,425 shares. The position is held across three Sands funds鈥擲ands Capital Ventures Discovery Fund III (1,124,729 shares, 1.9%), Sands Capital Global Venture Fund II (1,146,173 shares, 1.9%) and Sands Capital Life Sciences Pulse Fund (1,146,173 shares, 1.9%)鈥攚ith Sands Capital Alternatives acting as investment manager and Frank M. Sands retaining ultimate voting and investment power. The filing reports shared voting and dispositive power rather than sole control and includes a certification that the securities were not acquired to influence control.
Acumen Pharmaceuticals (ABOS) is a clinical-stage company advancing sabirnetug, an oligomer-targeted monoclonal antibody for Alzheimer鈥檚 disease. The company completed enrollment in its Phase 2 ALTITUDE-AD trial in March 2025 after initiating dosing in May 2024, and its Phase 1 INTERCEPT-AD topline results met primary and secondary objectives in July 2023. As of June 30, 2025, Acumen held $166.2 million of cash and marketable securities and reported working capital of $123.5 million, which management believes funds operations into early 2027.
Operating results reflect rapidly higher development spending: research and development expense rose to $62.4 million for the six months ended June 30, 2025 (up 95% year-over-year), driving a net loss of $69.7 million for the same period and an accumulated deficit of $394.9 million. The company has a $31.6 million term loan with embedded derivatives and an effective interest rate around 14% for the period. In July 2025 Acumen entered a collaboration with JCR with potential payments and milestones up to $555 million plus royalties.
Acumen Pharmaceuticals reported that it has furnished an earnings press release and posted an updated investor presentation that reflects the companys cash, cash equivalents and marketable securities balance as of June 30, 2025. The filing states these materials are furnished as Exhibits 99.1 and 99.2 and explicitly notes that the furnished information is not being "filed" under the Exchange Act and is not incorporated by reference in other securities filings.
The Form 8-K does not include numeric financial results within the filing itself; instead it directs readers to the furnished press release and presentation for details. The company also states that the submission is not an admission as to materiality of any Regulation FD disclosures.
FAQ
What is the current stock price of Acumen Pharmaceuticals (ABOS)?
What is the market cap of Acumen Pharmaceuticals (ABOS)?
